Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain.

Vertex has inked a long-term supply agreement with Swiss manufacturing bigwig Lonza to crank out global commercial supply of Casgevy, Lonza said in a release Tuesday.